Claims for Patent: 6,753,006
✉ Email this page to a colleague
Summary for Patent: 6,753,006
| Title: | Paclitaxel-containing formulations |
| Abstract: | In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of a pharmaceutically active agent, wherein the agent is associated with a polymeric biocompatible material. |
| Inventor(s): | Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA) |
| Assignee: | American BioScience, Inc. (Santa Monica, CA) |
| Application Number: | 09/629,501 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,753,006 |
| Patent Claims: |
1. A unit dosage form of paclitaxel comprising a sealed vial containing a quantity of non-crystalline, cremophor-free paclitaxel suitable for administration to a human over an
administration period no greater than about 3 hours, wherein said quantity is sufficient to deliver a dose between 30-1000 mg/m.sup.2 over said administration period.
2. A unit dosage form according to claim 1, wherein said dose is between 50-300 mg/m.sup.2. 3. A unit dosage form according to claim 1, wherein said dose is between 175-700 mg/m.sup.2. 4. A unit dosage form of paclitaxel comprising a sealed vial containing a quantity of non-crystalline, cremophor-free paclitaxel suitable for administration to a human with a treatment cycle less than about 3 weeks, wherein said quantity is sufficient to deliver a dose between 30-1000 mg/m.sup.2. 5. A unit dosage form according to claim 4, wherein said dose is between 50-300 mg/m.sup.2. 6. A unit dosage form according to claim 4, wherein said dose is between 175-700 mg/m.sup.2. 7. A unit dosage form of paclitaxel comprising an article of manufacture, wherein said article comprises a sealed vial containing a quantity of non-crystalline, cremophor-free paclitaxel suitable for administration to a human over an administration period no greater than about 3 hours, wherein said quantity is sufficient to deliver a dose between 30-1000 mg/m.sup.2 over said administration period. 8. A unit dosage form according to claim 7, wherein said dose is between 50-300 mg/m.sup.2. 9. A unit dosage form according to claim 7, wherein said dose is between 175-700 mg/m.sup.2. 10. A unit dosage form according to claim 7, wherein said administration is accomplished as a single dose. 11. A stable, sterile, nonpyrogenic, nonaqueous formulation of paclitaxel wherein the formulation contains a sufficient quantity of non-crystalline, cremophor-free paclitaxel to allow systemic administration at a dose in the range of about 30 mg/m.sup.2 to about 1000 mg/m.sup.2. 12. A formulation according to claim 11, wherein said dose is between 175-700 mg/m.sup.2. 13. A formulation according to claim 11, wherein said dose is between 50-300 mg/m.sup.2. 14. A formulation according to claim 11, wherein said administration is accomplished as a single dose. |
